The rise of GLP-1 receptor agonists such as Semaglutide, Liraglutide, and Tirzepatide (with common brands like Ozempic, Mounjaro) has transformed the treatment of obesity and type 2 diabetes. These medications have helped millions of people achieve significant weight loss, improve blood sugar control, and reduce cardiovascular risk. However, as more people remain on these medications for longer periods, questions are emerging about their potential effects on bone health and o
